Suggestions
Clifford Stocks
Chief Executive Officer at OncoResponse, Inc.
Clifford J. Stocks is the Founder and Chief Executive Officer of OncoResponse Inc., a clinical-stage, immuno-oncology biotech company developing cancer immunotherapies.13 He has been in this role since October 2015, bringing over 30 years of experience in the biotech industry.23
Prior to founding OncoResponse, Stocks served as:
- Chief Executive Officer at Theraclone Sciences, Inc. (December 2011 - May 2016)3
- Chief Business Officer at Calistoga Pharmaceuticals (March 2009 - April 2011)3
- Vice President of Business Development at ICOS Corporation (February 1992 - February 2007)3
Stocks played a key role in several significant business transactions, including:
- Leading the acquisition of Calistoga Pharmaceuticals by Gilead for $600 million in 201112
- Contributing to the $2.3 billion acquisition of ICOS Corporation by Lilly in 200713
His educational background includes:
- Master of Business Administration from the University of Chicago, Booth Graduate School of Business12
- Bachelor of Science degree in Biology from the University of Utah14
At OncoResponse, Stocks leads the company's efforts to develop novel therapeutics targeting the tumor microenvironment, using a proprietary B-cell discovery platform in collaboration with MD Anderson Cancer Center.3
Highlights
The recent decision by a #Texas judge to overturn the @FDA's 23-year-old approval of #mifepristone neglects decades of scientific evidence and sets a dangerous precedent for judicial interference in the regulatory process. I stand with the #FDA, and alongside my fellow #biotech leaders, as we call for support to help address this #publichealthissue. On Tuesday, 169 U.S. biopharmaceutical companies, executives and life science leaders filed an amicus brief with the U.S. Court of Appeals for the Fifth Circuit defending the FDA’s authority and jurisdiction to regulate all medications, including mifepristone. Read our open letter with more than 550 signatories across the biotech, biopharma and life sciences community, and join us in championing the need for science-based regulation, the FDA’s continued authority to regulate new medicines and protecting the future health of Americans: https://lnkd.in/ggC2eWBW
Kamal D. Puri #Kudos You are truly an inspiration to all of us #InspirationalLeader
